PT  - JOURNAL ARTICLE
AU  - Anthony Nguyen
AU  - Michel Pellerin
AU  - Louis P. Perrault
AU  - Michel White
AU  - Anique Ducharme
AU  - Normand Racine
AU  - Michel Carrier
TI  - Experience with the SynCardia total artificial heart in a Canadian centre
AID  - 10.1503/cjs.003617
DP  - 2017 Dec 01
TA  - Canadian Journal of Surgery
PG  - 375--379
VI  - 60
IP  - 6
4099  - http://canjsurg.ca/content/60/6/375.short
4100  - http://canjsurg.ca/content/60/6/375.full
SO  - CAN J SURG2017 Dec 01; 60
AB  - Background: The SynCardia total artificial heart (TAH) provides complete circulatory support by replacing both native ventricles. Accepted indications include bridge to transplantation and destination therapy. We review our experience with TAH implantation during a period when axial flow pump became available.Methods: We retrospectively analyzed the demographics, clinical characteristics and survival of all patients receiving the TAH.Results: From September 2004 to November 2016, 13 patients (12 men, mean age 45 ± 13 yr) received the TAH for refractory cardiogenic shock secondary to idiopathic (56%) or ischemic (17%) cardiomyopathy and to other various causes (33%). Before implantation, mean ejection fraction was 14% ± 4%, 7 (54%) patients had previous cardiac surgery, 4 (31%) were on mechanical ventilation, and 3 (23%) patients were on dialysis. The mean duration of TAH support was 46 ± 40 days. Three (23%) patients died while on support after a mean of 15 days. Actuarial survival on support was 77% ± 12% at 30 days after implantation. Complications on support included stroke (n = 1, 8%), acute respiratory distress syndrome requiring prolonged intubation (n = 5, 38%) and acute renal failure requiring temporary dialysis (n = 5, 38%). Ten (77%) patients survived to be transplanted after a mean of 52 ± 42 days of support. Actuarial survival rates after transplant were 67% ± 16% at 1 month and 56% ± 17% at 1 year after transplantation.Conclusion: The TAH provides an alternative with low incidence of neurologic events in extremely fragile and complex patients waiting for heart transplantation. Complex and unusual anatomic conditions explained the current use of TAH.